Healthcare: Frustrating Flops, Plus Welcome to the Wrinkle Wars

What Gilead Sciences and Sangamo Therapeutics disappointing data means to investors and why Allergan may face a formidable foe in up-and-comer Evolus. Stocks: GILD, SGMO, AGN, EOLS

Om Podcasten

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.